Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Knudsen

Emergency Medical Services Blaine, WA Medical Doctor

NPI 1508952060 CMS profile 294890

1300 Peace Portal Dr, Unit 304, Blaine, WA 98230

Open in the dashboard

General payments

$3,545

102 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Knudsen of Blaine, WA is reported in the CMS Open Payments database as having received $3,545 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Emergency Medical Services profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $452 15
2024 General $207 12
2023 General $554 12
2022 General $368 12
2021 General $450 12
2020 General $306 8
2019 General $1,209 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Knudsen
  • Emergency Medical Services median
  • Middle half of Emergency Medical Services
  • National median

In program year 2025, general payments to John Knudsen were reported at $452. Among 443 Emergency Medical Services profiles paid that year, the median was $72 and the middle half received between $25 and $169.

Show as a table
Year John Knudsen Emergency Medical Services median Middle half National median
2019 $1,209 $62 $20–$162 $163
2020 $306 $37 $17–$119 $114
2021 $450 $58 $20–$133 $132
2022 $368 $61 $21–$156 $149
2023 $554 $58 $21–$173 $160
2024 $207 $62 $24–$161 $164
2025 $452 $72 $25–$169 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $573 20 payments
  2. AstraZeneca Pharmaceuticals LP $520 11 payments
  3. GlaxoSmithKline, LLC. $509 14 payments
  4. Lilly USA, LLC $268 9 payments
  5. Janssen Pharmaceuticals, Inc $267 8 payments
  6. Teva Pharmaceuticals USA, Inc. $248 8 payments
  7. Biohaven Pharmaceuticals, Inc. $214 3 payments
  8. Pfizer Inc. $211 9 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $189 2 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $144 7 payments
  11. Other $402 11 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,456 94 payments
  2. Education $90 8 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $346 7 payments
  2. TRELEGY ELLIPTA $312 8 payments
  3. Ozempic $282 12 payments
  4. XARELTO $267 8 payments
  5. Wegovy $220 4 payments
  6. NURTEC ODT $214 3 payments
  7. SHINGRIX $197 6 payments
  8. JARDIANCE $189 2 payments
  9. MOUNJARO $175 4 payments
  10. Kerendia $144 7 payments
  11. Other $1,589 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

3,219

Median for General Practice: 1,105

Drug cost

$312,972

Median for General Practice: $48,734

Branded share of claims

21.9%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 81 $71,607
Jardiance Empagliflozin Brand 66 $59,903
Ozempic Semaglutide Brand 62 $55,201
Xarelto Rivaroxaban Brand 27 $26,711
Mounjaro Tirzepatide Brand 14 $25,865
Farxiga Dapagliflozin Propanediol Brand 16 $14,988
Symbicort Budesonide/Formoterol Fumarate Brand 15 $5,426
Atorvastatin Calcium Generic 320 $4,892
Humalog Insulin Lispro Brand 14 $3,736
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 25 $3,693

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$48,774

Of which drugs: $372

Medicare patients

169

Average age 76

Services billed

748

80 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 31%
Ischemic heart disease 22%
Diabetes 21%
Chronic kidney disease 20%
Atrial fibrillation 16%
Heart failure 13%
Cancer 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 14 15 $329

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
  • SANOFI-AVENTIS U.S. LLC $35
$35 — —
Wegovy
  • Novo Nordisk Inc $24
$24 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $20
$20 — —
MOUNJARO
  • Lilly USA, LLC $19
$19 14 —
RYBELSUS
  • Novo Nordisk Inc $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medical Services in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record